IVU en El Embarazo-2
IVU en El Embarazo-2
IVU en El Embarazo-2
RESUMEN
RECOMENDACIONES EN MANEJO
ANTIBIÓTICO SUPRESOR
• Se recomienda inicio de manejo antibiótioc supresor a largo plazo
ante la presencia de 2 o más episodios de infección de vías
urinarias e incluso ante 2 episodios de Bacteriuria asintomática
• Se recomiendan los siguientes esquemas de antibioticoterapia
supresora
• Nitrofurantoína 100 mg vía oral cada noche
• Cefalexina 250mg vía oral cada noche
• Trimetropim 150mg vía oral cada noche (en segundo trimestre,
si se asocia con sulfas no se recomeinda su uso en tercer
trimestre)
Terapia de supresión antibiótica en dada la inhibición que ejerce
gestantes con riesgo de infección sobre el metabolismo de los
urinaria recurrente. Se considera inicio de folatos.
esquemas antibióticos a largo plazo, en
aquellos casos en los que se presenten Modelos alternativos de tratamiento y
infecciones de vías urinarias sintomáticas prevención de infección de vías
en 2 o más episodios separados. (28) urinarias en el embarazo
BIBLIOGRAFIA
1. Calegari S. Results of two treatment regimens for pyelonephritis during pregnancy and correlation
with pregnancy outcome. Rev Bras Ginecol Obstet. 2012; 34(8):369-75
2. Machado J. Evaluación de sensibilidad antibiótica en urocultivos de pacientes en primer nivel de
atención en salud de Pereira. Rev. salud pública. 2012; 14 (4): 710-719.
3. Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes J, et al. Presentation, pattern, and
natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients
presenting with suspected uncomplicated urinary tract infection in primary care: observational study.
BMJ. 2010; 340:b 5633.
4. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international
survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
Int J Antimicrob Agents. 2009; 34:407-13.
5. Lindsay N. Uncomplicated Urinary Tract Infections in Adults. Urol Clin N Am. 2008; 35:1–12.
6. Fihn SD. Acute uncomplicated urinary tract infection in women. N Engl J Med. 2003; 349:259–66.
7. Chung A, Arianayagam M, Rashid P. Bacterial cystitis in women. Aust Fam Physician.2010; 39:295-8.
8. Pavón Goméz NJ. Diagnóstico y tratamiento de infección de las vías urinarias en embarazadas que
acuden a Emergencia y consulta externa del Hospital Bertha Calderón Roque en Managua,
Nicaragua Perinatol Reprod Hum 2013; 27 (1): 15-20
9. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database of
Systematic Reviews 2007
10. Christensen B.. Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which
antibiotics are appropriate to treat bacteriuria of pregnancy? International Journal of Antimicrobial
Agents 17 (2001) 283–285
11. Brumbaugh A. and Mobley H. Preventing urinary tract infection: progress toward an effective
Escherichia coli vaccine. Expert Rev Vaccines. 2012; 11(6): 663–676. doi:10.1586/erv.12.36.
12. Villar J, Widmer M, Lydon-Rochelle MT, Gulmezoglu AM, Roganti A. Duration of treatment for
asymptomtic bacteriuria during pregnancy. Cochrane Database of Systematic Reviews 2000, Issue 2.
13. Macejko A.; Schaeffer A. Asymptomatic Bacteriuria and Symptomatic Urinary Tract Infections During
Pregnancy. Urol Clin N Am 2007; 34: 35–42.
14. Guinto VT, De Guia B, Festin MR, Dowswell T. Different antibiotic regimens for treating asymptomatic
bacteriuria in pregnancy. Cochrane Database of Systematic Reviews 2010
15. Chávez-Valencia R. Patrones de resistencia antimicrobiana y etiología en infecciones urinarias no
complicadas. Gac Med Mex 2010; 146: 94-9
16. Nicolle L. Asymptomatic bacteiruria. Current Review. Urinary tract infections. 2014; 27 (1)
17. Abarzúa CF, Zajer C, Donoso B, Belmar J, Riveros JP, González BP et al. Reevaluación de la
sensibilidad antimicrobiana de patógenos urinarios en el embarazo. Rev Chil Obstet Ginecol [en
línea] 2002
18. South Australian Perinatal Practice Guidelines urinary tract infections in pregnancy. Department of
Health, Government of South Australia. All rights reserved. 29/04/2013. Disponible en:
http://www.sahealth.sa.gov.au
19. Grabe M., Bjerklund‑Johansen T.E., Botto H., Çek M.,. Naber K.G, Tenke P., Wagenlehner F. Guía
clínica sobre las infecciones urológicas. European Association of Urology 2010. Disponible en:
http://www.uroweb.org/gls/pdf/spanish/17-
%20GUIA%20CLINICA%20SOBRE%20LAS%20INFECCIONES%20UROLOGICAS.pdf
20. WidmerM, Gülmezoglu AM,Mignini L, Roganti A.Duration of treatment for asymptomatic bacteriuria
during pregnancy. Cochrane Database of Systematic Reviews 2011
21. Grabe M., Bjerklund‑Johansen T.E., Botto H., Çek M.,. Naber K.G, Tenke P., Wagenlehner F.
Guía.clínica sobre las infecciones urológicas. European Association of Urology 2010. Disponible en:
http://www.uroweb.org/gls/pdf/spanish/17-
%20GUIA%20CLINICA%20SOBRE%20LAS%20INFECCIONES%20UROLOGICAS.pdf
22. Vazquez JC, Villar J. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane
Database Syst Rev 2010
23. Scottish Intercollegiate Guidelines Network (SIGN). Sign 88: Management of suspected bacterial
urinary tract infection in adults. A national clinical guideline. Edinburgh:SIGN; 2012. Disponible en
http://www.sign.ac.uk/pdf/sign88.pdf
24. Vouloumanou EK, Karageorgopoulos DE, Kazantzi MS, Kapaskelis AM, Falagas ME. Antibiotics
versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized
controlled trials. J Infect 2009; 64(1):16-24.
25. Federação Brasileira das Associações de Ginecologia e Obstetrícia (FEBRASGO). Comissões
Nacionais Especializadas Ginecologia e Obstetrícia. Manual de orientação: gestação de alto risco.
Infecção urinária na gestação. Rio de Janeiro: FEBRASGO; 2011.p. 197-204.
26. Ferreira F., M.D. Urinary infection during pregnancy: a profile of resistance to treatment in the General
Hospital in Neiva, Colombia. Revista Colombiana de Obstetricia y Ginecología Vol. 56 No.3. 2005.
239-243
27. Casas R. MD. The prevalence of ampicillin resistance in pregnant women suffering from urinary tract
infections in the San José Teaching Hospital. Popayán, Colombia 2007-2008. Revista Colombiana de
Obstetricia y Ginecología Vol. 60 No. 4. 2009; 334-338
28. Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Interventions for preventing recurrent
urinary tract infection during pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 11.
29. Masson P. Meta-analyses in Prevention and Treatment of Urinary Tract Infections. Infect Dis Clin N
Am 23 (2009) 355–385
30. Lavender R. Cranberry juice - the facts. Nursing Times: Nursing Times (NT) Plus Supplement
2000;96(40):11–2.
31. Guay DR. Cranberry and urinary tract infections. Drugs 69;7:775–807.
32. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry
proanthocyanidins and uropathogenic bacterial antiadhesion activity. Phytochemistry
2005;66(18):2281-91
33. Lavigne JP, Bourg G, Combescure C, Botto H, Sotto A. Invitro and in-vivo evidence of dose-
dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial
Vaccinium macrocarpon (cranberry) capsules. Clinical Microbiology and Infection 2008;14(4): 350–5
34. Ohnishi R, Ito H, Kasajima N, Kaneda M, Kariyama R, Kumon H, et al.Urinary excretion of
anthocyanins in humans after cranberry juice ingestion. Bioscience, Biotechnology and Biochemistry
2006;70(7):1681-7.
35. Pérez-López FR, Haya J, Chedraui P. Vaccinium macrocarpon: An interesting option for women with
recurrent urinary tract infections and other health benefits. Journal of Obstetrics and Gynaecology
Research 2009;35(4): 630-9
36. Mills E, Dugoua JJ, Perri D, Koren G: Herbal Medicines in Pregnancy and Lactation. An evidence-
Based Approach. Taylor&Francis Group: London and New York; 2006
37. Jepson RG, Williams G, Craig JC: Cranberries for preventing urinary tract infections. Cochrane
Database Syst Rev 2012, 10:CD001321.
38. Hess HM, Miller RK: Herbs during pregnancy. In Drugs During Pregnancy and Lactation. 2nd edition.
Edited by Schaefer C, Peters P, Miller R. London: Elsevier; 2007:485–501.
39. Eke AC, Akarolo-Anthony SN, Enumah AP. Cranberries for treating asymptomatic bacteriuria during
pregnancy. Cochrane Database of Systematic Reviews 2012
40. Heitmann et al. Pregnancy outcome after use of cranberry in pregnancy – the Norwegian mother and
child cohort study BMC Complementary and Alternative Medicine 2013, 13:345
41. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991;
4(1):80–128. [PubMed: 1672263]
42. Vann WF, Schmidt MA, Jann B, Jann K. The structure of the capsular polysaccharide (K5 antigen) of
urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J
Biochem. 1981; 116(2):359–364. [PubMed: 7018909]
43. Rappuoli, R.; Bagnoli, F. Vaccine Design: Innovative Approaches and Novel Strategies. Caister
Academic; Norfolk, UK: 2011. Well-organized review of vaccine design strategies, including reverse
vaccinology
44. Meiland R, Geerlings SE, Langermann S, Brouwer EC, Coenjaerts FE, Hoepelman AI.
Fimchantiserum inhibits the adherence of Escherichia coli to cells collected by voided urine
specimens of diabetic women. J Urol. 2004; 171(4):1589–1593.
45. Medimmune, Inc. [Accessed on 10 march 2014] Annual Report. 2002.
www.astrazeneca.com/Investors/Annual-reports
46. Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HL. Escherichia coli global gene expressionin
urine from women with urinary tract infection. PLoS Pathog. 2010; 6(11):e1001187.
47. Eisenstein BI. Phase variation of type 1 fimbriae in Escherichia coli is under transcriptional control.
Science. 1981; 214(4518):337–339.
48. Nowicki B, Rhen M, Väisänen-Rhen V, Pere A, Korhonen TK. Immunofluorescence study offimbrial
phase variation in Escherichia coli KS71. J Bacteriol. 1984; 160(2):691–695
49. Grischke EM, Rüttgers H. Treatment of bacterial infections of the female urinary tract by immunization
of the patients. Urol Int. 1987; 42(5):338–341. [PubMed: 3324441]
50. Knuf M, Habermehl P, Faber J, et al. Assessment of nine candidate DTP-vaccines with reduced
amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Vaccine. 2006; 24(27–28):5627–5636. [PubMed: 16740348]
51. Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC. Multicenter UTI Study Group.
A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients
with recurrent urinary tract infections. Eur Urol. 2005; 47(4):542–548. Discussion 548. [PubMed:
15774256]
52. Kim KS, Kim JY, Jeong IG, et al. A prospective multi-center trial of Escherichia coli extract forthe
prophylactic treatment of patients with chronically recurrent cystitis. J Korean Med Sci. 2010;
25(3):435–439. [PubMed: 20191044